deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL NCT00056173

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)

Sponsor: Aptose Biosciences Inc.

Conditions Carcinoma, Renal Cell Metastases, Neoplasm
Interventions GTI-2040
Updated 6 times since 2017 Last updated: Jan 4, 2008 Started: Mar 31, 2002 Primary completion: Dec 31, 2004
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Carcinoma, Renal Cell and Metastases, Neoplasm, this trial is completed. The trial is conducted by Aptose Biosciences Inc. and has accumulated 6 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aptose Biosciences Inc.
  • University of Chicago
  • Wake Forest University
Data source: Aptose Biosciences Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations